Veru Inc (VERU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.64-0.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VERU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 89.6% |
| Our one-year growth estimate | diamond | -69.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 158.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VERU — debt issuance
Dated 2026-07-02
Entry into a Material Definitive Agreement On July 2, 2026, Veru Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”), with Oppenheimer & Co. Inc. and Canaccord Genuity LLC (each, a “Sales Agent” and, together, the “Sales Agents”), as sales agents, pursuant to which the Company may issue and sell, from time to time, to or through the applicable Sales Agent (the “Designated Sales Agent”), shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”…
Why it matters: This deal is important for the Phase 2b PLATEAU trial. It could improve the study's trust and results.
Supportive ifA public announcement will confirm the supply deal is active and helping the trial.
Worry ifDelays or issues reported in the supply agreement that hinder the trial's progress.
Why it matters: Full enrollment is crucial for timely results. Any delays could impact the trial timeline and investor confidence.
Watch forEnrollment stays steady or goes up. This shows strong interest and participation.
Also watch forEnrollment stops or goes down. This may show problems with the trial.
Why it matters: This agreement is crucial for the Phase 2b PLATEAU trial. Successful collaboration could enhance trial outcomes.
Supportive ifLook for news about a successful supply chain or more help from Novo Nordisk.
Worry ifReports of delays or issues in the supply agreement affecting the trial.
Why it matters: Updates on cash will indicate financial health and ability to fund clinical trials. This is crucial for ongoing operations.
Watch forThe cash position gets much better after the debt issuance on July 2, 2026.
Also watch forCash position declines or remains stagnant despite the debt issuance.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$219 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $817 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,282 loss on $10,000 · 52.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Progress in this area may lead to future money and market growth.
Supportive ifLook for good results or milestones in enobosarm trials.
Worry ifThere are no updates or bad results from enobosarm clinical trials.
Why it matters: The interim results will show if enobosarm and semaglutide help with weight loss. This could affect future studies and market chances.
Supportive ifInterim analysis results from the Phase 2b PLATEAU trial are reported in Q1 2027.
Worry ifThe interim analysis is delayed beyond Q1 2027.
Why it matters: The interim results will show if enobosarm and semaglutide help with weight loss. This could impact future development plans.
Supportive ifThe interim analysis shows a big drop in total body weight or fat after 32 weeks.
Worry ifInterim results show no significant change in total body weight or fat mass.
Why it matters: Getting the patent would help Veru's market position and protect its ideas until at least 2044.
Supportive ifThe U.S. patent for enobosarm is officially issued by the USPTO.
Worry ifThe patent is delayed or rejected by the USPTO.
Why it matters: Better results in operating loss may mean better financial health. It can also show more efficiency.
Supportive ifOperating loss decreases further from $7.7 million in Q2 2026.
Worry ifOperating loss goes up or stays the same compared to last quarter.